The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended granting approval to Novo Nordisk India for its proposed update to ...
A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be ...
Elevating Aesthetic Dermatology in Rockville with Innovative Med Spa Services Under CEO Janine Shore’ Rockville, United States – December 11, 2025 / Shore Dermatology / Shore Dermatology, a ...
Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...
The ZENITH trial showed sotatercept significantly reduced death, transplant, or hospitalization risk in advanced PAH, leading ...
Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...
A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...
Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk ...
Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...
FDA may expedite approval timeline for Eli Lilly's weight-loss treatment, potentially moving decision date to late March from ...
Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...
Healthcare giant Novo Nordisk A/S (NYSE:NVO)’s shares were downgraded by Argus Research to Hold from Buy on December 8th, The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback